CY1124894T1 - Θεραπευτικη αντιμετωπιση χολοστατικου κνησμου με σελαδελπαρη - Google Patents

Θεραπευτικη αντιμετωπιση χολοστατικου κνησμου με σελαδελπαρη

Info

Publication number
CY1124894T1
CY1124894T1 CY20221100017T CY221100017T CY1124894T1 CY 1124894 T1 CY1124894 T1 CY 1124894T1 CY 20221100017 T CY20221100017 T CY 20221100017T CY 221100017 T CY221100017 T CY 221100017T CY 1124894 T1 CY1124894 T1 CY 1124894T1
Authority
CY
Cyprus
Prior art keywords
seladelpar
cholestatic
itching
therapeutic treatment
treatment
Prior art date
Application number
CY20221100017T
Other languages
Greek (el)
English (en)
Inventor
Pol Boudes
Charles A. Mcwherter
Alexandra S. STEINBERG
Original Assignee
Cymabay Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics, Inc. filed Critical Cymabay Therapeutics, Inc.
Publication of CY1124894T1 publication Critical patent/CY1124894T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Ladders (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CY20221100017T 2017-09-26 2022-01-07 Θεραπευτικη αντιμετωπιση χολοστατικου κνησμου με σελαδελπαρη CY1124894T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762563395P 2017-09-26 2017-09-26
PCT/US2018/052490 WO2019067373A1 (en) 2017-09-26 2018-09-24 TREATMENT OF CHOLESTATIC PRURIT

Publications (1)

Publication Number Publication Date
CY1124894T1 true CY1124894T1 (el) 2023-01-05

Family

ID=64564950

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100017T CY1124894T1 (el) 2017-09-26 2022-01-07 Θεραπευτικη αντιμετωπιση χολοστατικου κνησμου με σελαδελπαρη

Country Status (26)

Country Link
US (2) US20190105291A1 (enExample)
EP (3) EP3687523B1 (enExample)
JP (1) JP7023371B2 (enExample)
KR (1) KR102376794B1 (enExample)
CN (1) CN111132675B (enExample)
AU (2) AU2018342323B2 (enExample)
BR (1) BR112020005074A2 (enExample)
CA (1) CA3076614C (enExample)
CY (1) CY1124894T1 (enExample)
DK (1) DK3973959T3 (enExample)
ES (2) ES3012120T3 (enExample)
FI (1) FI3973959T3 (enExample)
HR (2) HRP20250022T1 (enExample)
HU (2) HUE070033T2 (enExample)
IL (2) IL273569B (enExample)
LT (2) LT3973959T (enExample)
MX (1) MX392537B (enExample)
PL (2) PL3973959T3 (enExample)
PT (2) PT3687523T (enExample)
RS (1) RS62790B1 (enExample)
SG (1) SG11202002253SA (enExample)
SI (2) SI3687523T1 (enExample)
SM (1) SMT202200171T1 (enExample)
UA (1) UA125600C2 (enExample)
WO (1) WO2019067373A1 (enExample)
ZA (1) ZA202001646B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
ES2701094T3 (es) 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR20210078515A (ko) 2018-10-18 2021-06-28 아비어, 인크. 만성 신장 질환-연관 소양증의 치료 방법 및 장치
KR20220140762A (ko) * 2020-02-10 2022-10-18 장피트 엘라피브라노에 의한 원발 담즙성 담관염의 치료
CN115884765A (zh) 2020-08-26 2023-03-31 基恩菲特公司 用于治疗原发性胆汁性胆管炎的组合物和方法
CN116490191A (zh) * 2020-10-20 2023-07-25 葛兰素史克知识产权第二有限公司 治疗胆汁淤积性瘙痒的方法
RS65546B1 (sr) 2021-02-01 2024-06-28 Cymabay Therapeutics Inc Tretman holangiopatija sa seladelparom
US20240252499A1 (en) 2023-01-29 2024-08-01 Cymabay Therapeutics, Inc. Treatment of uremic pruritus
KR20250139304A (ko) * 2023-01-29 2025-09-23 사이머베이 쎄라퓨틱스, 인코퍼레이티드 만성 소양증 피부병의 치료
WO2025250635A1 (en) * 2024-05-28 2025-12-04 Avior, Inc. Use of nalmefene hydrochloride buccal films in treating liver disease associated pruritus
WO2026030533A1 (en) 2024-07-31 2026-02-05 Cymabay Therapeutics, Inc. Seladelpar for use in treating liver disease
US20260207538A1 (en) 2024-12-20 2026-07-23 Gilead Sciences, Inc. Combinations for liver disease
CN121023009A (zh) * 2025-10-31 2025-11-28 浙江大学医学院附属妇产科医院(浙江省妇女医院、浙江省妇女保健院) 基于唾液样本的妊娠期肝内胆汁淤积症易感基因多重pcr—ngs筛查方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA87467C2 (xx) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
ES2701094T3 (es) * 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
JP2020533339A (ja) * 2017-09-13 2020-11-19 ノバルティス アーゲー Fxrアゴニストを含む組合せ

Also Published As

Publication number Publication date
EP3973959B1 (en) 2024-12-11
RU2020114644A (ru) 2021-10-27
US20190105291A1 (en) 2019-04-11
MX2020007273A (es) 2022-05-23
CA3076614C (en) 2023-02-07
IL288340B2 (en) 2023-05-01
WO2019067373A1 (en) 2019-04-04
SG11202002253SA (en) 2020-04-29
AU2021254641A1 (en) 2021-11-18
ES2902349T3 (es) 2022-03-28
HUE070033T2 (hu) 2025-05-28
HRP20212010T1 (hr) 2022-04-01
LT3687523T (lt) 2022-03-25
EP4523744A3 (en) 2025-06-04
PL3687523T3 (pl) 2022-02-21
UA125600C2 (uk) 2022-04-27
CN111132675A (zh) 2020-05-08
PL3973959T3 (pl) 2025-03-24
DK3973959T3 (da) 2025-01-20
LT3973959T (lt) 2025-01-10
AU2021254641B2 (en) 2022-02-24
FI3973959T3 (fi) 2025-02-03
IL273569A (en) 2020-05-31
EP3973959A1 (en) 2022-03-30
AU2018342323A1 (en) 2020-04-16
SMT202200171T1 (it) 2022-05-12
US20210283078A1 (en) 2021-09-16
EP4523744A2 (en) 2025-03-19
HRP20250022T1 (hr) 2025-03-14
HUE057377T2 (hu) 2022-05-28
IL288340B1 (en) 2023-01-01
EP3973959B8 (en) 2025-01-15
ZA202001646B (en) 2021-08-25
SI3973959T1 (sl) 2025-03-31
AU2018342323B2 (en) 2021-09-23
KR20200058458A (ko) 2020-05-27
PT3973959T (pt) 2025-01-24
BR112020005074A2 (pt) 2020-09-15
SI3687523T1 (sl) 2022-05-31
MX392537B (es) 2025-03-04
EP3687523B1 (en) 2021-11-03
IL288340A (en) 2022-01-01
PT3687523T (pt) 2021-12-06
EP3687523A1 (en) 2020-08-05
ES3012120T3 (en) 2025-04-08
NZ762976A (en) 2021-11-26
IL273569B (en) 2021-12-01
CA3076614A1 (en) 2019-04-04
JP2020535225A (ja) 2020-12-03
KR102376794B1 (ko) 2022-03-18
RU2020114644A3 (enExample) 2022-02-14
JP7023371B2 (ja) 2022-02-21
CN111132675B (zh) 2023-04-25
RS62790B1 (sr) 2022-02-28

Similar Documents

Publication Publication Date Title
MX392537B (es) Tratamiento del prurito colestasico.
CY1122602T1 (el) Αντιμετωπιση των nafld και nash
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
IL268709A (en) Radiation source
CY1125465T1 (el) Σελαδελπαρη για αγωγη της πρωτοπαθους χολικης χολαγγειιτιδας
ECSP17015977A (es) Terapia de combinacion
CY1120927T1 (el) Αγωγη των ενδοηπατικων χολοστατικων νοσων
ECSP17029371A (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
IL264203A (en) Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
DK3612624T3 (da) Genterapi
DK3622953T3 (da) Kombinationsbehandling af cancer
CL2020000902A1 (es) Conexión flexible antisísmica
PT3319995T (pt) Terapêutica combinada de um conjugado anticorpo anti-her2-fármaco com um inibidor de bcl-2
EP3636271C0 (en) THERAPEUTIC AGENT AGAINST DILATED CARDIOMYOPATHY
JOP20200034B1 (ar) تركيبة للتنشيط المتحكم فيه للمبيض
EP3843748C0 (en) COMBINATION THERAPY
EP3600371A4 (en) AGAINST ERG THERAPY
JOP20200056A1 (ar) تركيب غلاية
IT201700100732A1 (it) Sorgente ionica
EP3717020A4 (en) RAS TARGETED THERAPEUTIC
DK3552506T3 (da) Underlivsbeklædning
EP3801506A4 (en) POLYTHERAPY
EP3515442A4 (en) ADJUSTMENT
GEAP201814364A (en) Radial-squeezing machine
GEAP201814238A (en) Wall heat-insulating block